Restrictive Lung Disease Pathology

Fundamental Mechanism: Reduced Compliance and Elastic Recoil

• Fibrosis-mediated reduction in compliance: Deposition of collagen (types I and III) and elastin in the interstitial space increases elastic recoil; patients compensate by increasing respiratory effort, resulting in paradoxical reduction in dynamic compliance despite increased elastic recoil
• Alveolar-capillary membrane thickening: Interstitial edema, fibrosis, and inflammation increase diffusion distances, creating a restrictive pattern on pulmonary function testing (PFT)
• Loss of alveolar surface area: Progressive fibrosis causes architectural distortion, honeycombing (replacement of normal lung with cystic air spaces), and resorption atelectasis

Cellular and Molecular Events in Fibrotic Restrictive Disease

• Epithelial-mesenchymal transition (EMT): Alveolar epithelial cells, particularly type II pneumocytes, undergo transdifferentiation into fibroblasts via activation by transforming growth factor-beta (TGF-β), interleukin-6 (IL-6), and other cytokines
• Myofibroblast proliferation and activation: Fibroblasts differentiate into myofibroblasts (characterized by α-smooth muscle actin expression and contractile apparatus) through TGF-β signaling; these cells produce excessive extracellular matrix (ECM) components
• Aberrant wound-healing response: Normal lung repair mechanisms fail to resolve; instead of resolution, there is persistent activation of transforming growth factor-beta (TGF-β) signaling through TGF-β receptor I (ALK5) and SMAD2/3 pathways, perpetuating fibroblast recruitment and ECM deposition
• Dysregulated apoptosis: Loss of apoptosis in myofibroblasts and alveolar epithelial cell apoptosis paradoxically increases, contributing to barrier dysfunction and fibrotic progression

Inflammatory and Fibrotic Cascade in IPF (Prototypical Fibrotic Disease)

• Initial epithelial injury: Repetitive microinjury to alveolar epithelium (from oxidative stress, infection, aspiration, or genetic predisposition) triggers an innate immune response
• Macrophage and inflammatory cell activation: Alveolar macrophages produce TNF-α, IL-1β, IL-6, and TGF-β; recruitment of CD4+ Th2 cells and eosinophils amplifies the Th2 response
• Fibroblast niche establishment: Injured epithelium and inflammatory cytokines create a microenvironment promoting fibroblast proliferation; platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) further drive proliferation
• Excessive ECM deposition: Myofibroblasts deposit collagen faster than matrix metalloproteinases (MMPs) can degrade it, resulting in net accumulation of fibrotic tissue

Parenchymal and Functional Consequences

• Alveolar-capillary block: Thickened interstitium impairs oxygen diffusion; diffusion capacity (DLCO) decreases disproportionately relative to FVC, creating characteristic PFT pattern
• Ventilation-perfusion (V/Q) mismatch: Fibrotic reorganization causes areas of poor ventilation with preserved perfusion (low V/Q units) and destruction of capillary bed
• Hypoxemia mechanisms:
• Diffusion-limited hypoxemia (worsens with exercise when capillary transit time shortens)
• V/Q mismatch (improved by supplemental oxygen)
• Hypoventilation (late-stage disease)
• Increased work of breathing: Reduced compliance increases the work required for each breath; patients develop tachypnea and dyspnea even at rest or with minimal exertion

Pulmonary Fibrosis (Fibrotic Restrictive Diseases)

• Idiopathic Pulmonary Fibrosis (IPF)
• Usual interstitial pneumonia (UIP) pattern: Heterogeneous, patchy fibrosis with temporal heterogeneity (coexistence of fibrotic foci and normal-appearing parenchyma), subpleural and basal predominance
• Risk factors: Advanced age (>60 years), male gender, cigarette smoking, gastroesophageal reflux disease (GERD)
• Genetic predisposition: Polymorphisms in MUC5B, TERT, TERC; familial pulmonary fibrosis (FPF) in 3-5% of cases

• Connective tissue disease-associated pulmonary fibrosis
• Systemic sclerosis (scleroderma): Most common; exhibits nonspecific interstitial pneumonia (NSIP) pattern or UIP
• Rheumatoid arthritis, systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD)

• Hypersensitivity Pneumonitis (HP)
• Antigen exposure: Organic antigens (thermophilic actinomycetes in moldy hay—farmer's lung), isocyanates, metal dusts
• Acute phase: Neutrophilic infiltration; chronic phase: Granulomatous inflammation with poorly formed non-caseating granulomas and fibrosis

• Occupational and Environmental Exposures
• Silicosis: Inhalation of crystalline silica dust; classic finding of eggshell calcification of hilar lymph nodes
• Asbestosis: Asbestos fiber inhalation (shipyard workers, insulation installers); associated with pleural plaques, pleural thickening, and mesothelioma
• Coal worker's pneumoconiosis (CWP): Coal dust inhalation; progressive massive fibrosis (PMF) in advanced stages
• Talcosis: Talc inhalation; fibrosis with characteristic talc crystals visible on polarized light microscopy

• Drug-Induced Pulmonary Fibrosis
• Bleomycin (chemotherapy agent): Dose-dependent fibrosis
• Methotrexate, nitrofurantoin, amiodarone

• Radiation-Induced Pulmonary Fibrosis
• Fibrosis developing 6-24 months after thoracic radiation therapy; dose-dependent risk

Alveolar-Filling Diseases (Restrictive Pattern)

• Pulmonary Edema: Hydrostatic (heart failure, mitral stenosis) or increased permeability (ARDS, sepsis)
• Pneumonia: Bacterial, viral, fungal consolidation
• Pulmonary Hemorrhage: Anti-GBM disease (Goodpasture syndrome), ANCA-associated vasculitis (granulomatosis with polyangiitis—GPA), immune complex vasculitis
• Pulmonary Alveolar Proteinosis: Accumulation of surfactant-like lipoprotein in alveolar spaces; autoimmune (GM-CSF neutralizing antibodies), congenital, or secondary

Granulomatous and Inflammatory Restrictive Diseases

• Sarcoidosis: Multisystem disease with non-caseating granulomatous inflammation affecting lungs, lymph nodes, and other organs; predominantly affects middle-aged adults and African Americans
• Tuberculosis: Granulomatous inflammation with caseating necrosis (central cheese-like necrosis surrounded by epithelioid cells and Langhans giant cells)
• Fungal infections: Histoplasmosis, coccidioidomycosis, blastomycosis

Pleural and Chest Wall Restrictions

• Pleural fibrosis/thickening: Post-tuberculosis, asbestos exposure, empyema
• Kyphoscoliosis: Skeletal deformity reducing thoracic capacity
• Neuromuscular diseases: Myasthenia gravis, amyotrophic lateral sclerosis (ALS), Guillain-Barré syndrome (affecting respiratory musculature)

Other Important Causes

• Acute Respiratory Distress Syndrome (ARDS): Diffuse alveolar damage (DAD) with acute exudative phase (hyaline membrane formation) progressing to organizing/fibrotic phase
• Langerhans Cell Histiocytosis (LCH): Proliferation of Langerhans cells with Birbeck granules on electron microscopy; cystic lesions and fibrosis
• Lymphangitic Carcinomatosis: Metastatic tumor infiltration of pulmonary lymphatic vessels

Cardinal Symptoms and Functional Impact

• Progressive dyspnea on exertion (DOE): Typically insidious onset over months to years; reflects reduced lung compliance and increased work of breathing; worsened by exercise due to diffusion-limited hypoxemia
• Dry cough: Nonproductive cough resulting from epithelial irritation and interstitial inflammation; common in IPF, HP, and sarcoidosis
• Chest pain or pleurisy: Pleuritic pain (worse with breathing, movement) indicating pleural involvement
• Fatigue and constitutional symptoms: Nonspecific; more prominent in inflammatory/systemic diseases (sarcoidosis, CTD-ILD)

Physical Examination Findings with Morphological Correlates

• End-inspiratory crackles (Velcro crackles): Fine, dry, high-pitched crackles heard at lung bases and posteriorly; result from sudden reopening of collapsed alveoli during inspiration; hallmark of fibrotic ILD, especially IPF
• Clubbing of fingers and toes: Found in IPF, bronchiectasis-associated fibrosis, and some occupational lung diseases; unknown mechanism but associated with poor prognosis in IPF
• Cyanosis: Central cyanosis (blue discoloration of lips, tongue) indicating severe hypoxemia
• Tachypnea: Resting respiratory rate >20 breaths/minute reflecting increased work of breathing and hypoxemia
• Reduced lung sounds: Diminished breath sounds indicating parenchymal loss or fibrotic consolidation
• Signs of right heart failure (cor pulmonale): Peripheral edema, jugular venous distension, right ventricular heave; develop in advanced disease with pulmonary hypertension

Hypoxemia and Gas Exchange Abnormalities

• Exertional hypoxemia: Oxygen saturation (SpO₂) normal at rest but drops to <88% with exercise; reflects diffusion limitation worsening with increased capillary transit rates
• Respiratory alkalosis: Early (compensatory hyperventilation due to hypoxemia and increased airway resistance)
• Respiratory acidosis: Late-stage disease (respiratory muscle fatigue, hypoventilation)

Disease-Specific Clinical Patterns

• IPF: Insidious DOE, dry cough, clubbing, minimal constitutional symptoms; median age 60-70 years; rapid progression in some cases ("accelerated IPF")
• Hypersensitivity Pneumonitis: Acute form presents 4-8 hours after exposure (fever, chills, malaise, cough); chronic form develops insidiously after repeated exposure
• Sarcoidosis: Systemic symptoms (fever, weight loss, night sweats); extrapulmonary manifestations (erythema nodosum, anterior uveitis, hypercalcemia from 1,25-dihydroxyvitamin D3 production by granulomas)
• Occupational lung disease: Temporal relationship to occupational exposure; smoking history; progression despite cessation of exposure
• Drug-induced fibrosis: Temporal relationship to drug initiation; bleomycin-induced fibrosis typically develops within 2 years

Pulmonary Function Testing (PFT) Pattern

• Characteristic restrictive pattern:
• Reduced FVC (forced vital capacity) to <80% predicted
• Reduced TLC (total lung capacity) to <80% predicted
• Normal to elevated FEV₁/FVC ratio (>0.70 or 70%), distinguishing from obstructive disease
• Reduced DLCO (diffusion capacity for carbon monoxide) often disproportionately low relative to FVC; DLCO/VA (alveolar volume) ratio distinguishes restrictive from obstructive diseases with emphysema
• Flow-volume loop: Shows a restrictive pattern with proportionally reduced flows and volumes

Imaging Studies

• High-Resolution Computed Tomography (HRCT) of the Chest:
• Usual Interstitial Pneumonia (UIP) pattern:
• Subpleural, basilar-predominant distribution
• Reticular opacities (net-like pattern of thickened interlobular septa)
• Honeycombing (clustered cystic air spaces with no normal parenchyma intervening, representing end-stage fibrosis)
• Traction bronchiectasis (dilation of bronchi pulled open by surrounding fibrosis)
• When typical UIP pattern present on HRCT, biopsy may not be required for IPF diagnosis
• Nonspecific Interstitial Pneumonia (NSIP) pattern:
• Ground-glass opacities (increased attenuation without obscuration of vessels)
• Fibrosis less reticular; more uniform distribution (not strictly subpleural/basilar)
• Associated with CTD-ILD, some cases of idiopathic NSIP
• Hypersensitivity Pneumonitis pattern:
• Centrilobular distribution of ground-glass opacities
• Mosaic perfusion (patchwork of areas with normal and abnormal attenuation)
• Acute phase: Acute ground-glass; chronic phase: Fibrotic pattern similar to NSIP
• Organizing pneumonia pattern: Bronchocentric consolidation and peribronchovascular distribution
• Sarcoidosis pattern: Upper lobe/middle lobe predominant bilateral hilar lymphadenopathy with eggshell calcification; nodular opacities; less fibrosis than IPF
• Silicosis: Bilateral upper lobe-predominant nodules progressing to progressive massive fibrosis (PMF); eggshell hilar lymphadenopathy characteristic

• Plain Chest Radiograph: Less sensitive; may show reticular or reticulonodular opacities, but HRCT has superior resolution for fibrotic diseases

Histopathology (Obtained via Transbronchial Biopsy, Transbronchial Cryobiopsy, or Surgical Lung Biopsy)

• Usual Interstitial Pneumonia (UIP) Pattern:
• Patchy, heterogeneous fibrosis with temporal heterogeneity (coexistence of fibrotic foci with inflammatory infiltrates and normal-appearing parenchyma in the same specimen)
• Subpleural and paraseptal fibrosis (predominance in periphery and near pleura)
• Dense collagen deposition with architectural remodeling and honeycombing (cystic airspaces lined by columnar/cuboidal epithelium, representing dilated distal airways)
• Fibroblastic foci (microscopic foci of fibroblast proliferation at the

Immediate stabilization

• Supplemental oxygen: titrate to resting SpO₂ ≥90%; the ATS clinical practice guideline on home oxygen supports long-term oxygen for resting hypoxemia in fibrotic ILD and ambulatory oxygen for exertional desaturation. Oxygen corrects V/Q-mismatch hypoxemia but does not slow fibrosis.
• Treat the reversible driver first: remove the inciting antigen in hypersensitivity pneumonitis, stop the culprit drug (bleomycin, amiodarone, nitrofurantoin, methotrexate), remove the patient from ongoing dust exposure.

First-line disease-directed therapy

• Antifibrotics for IPF: the ATS/ERS/JRS/ALAT IPF guideline conditionally recommends pirfenidone (TGF-β/collagen-synthesis inhibitor) or nintedanib (intracellular tyrosine kinase inhibitor of PDGFR, FGFR, VEGFR). Both slow FVC decline; neither reverses established fibrosis.
• Immunosuppression for inflammatory/CTD-ILD: the ACR/CHEST guideline on ILD in systemic autoimmune rheumatic disease supports mycophenolate mofetil as a common first-line agent, with glucocorticoids used for inflammatory disease (not for IPF).
• Glucocorticoids for sarcoidosis and acute hypersensitivity pneumonitis: prednisone is standard for symptomatic pulmonary sarcoidosis.

Escalation / second-line

• Nintedanib for progressive pulmonary fibrosis of non-IPF cause, including systemic sclerosis–associated ILD.
• Biologics/cytotoxics in CTD-ILD: rituximab, tocilizumab, or cyclophosphamide for refractory or rapidly progressive disease.
• Pulmonary rehabilitation, influenza/pneumococcal/COVID-19 vaccination, GERD management, and smoking cessation are recommended supportive measures.

Definitive management

• Lung transplantation: the only intervention with a clearly demonstrated survival benefit in advanced IPF; antifibrotics slow FVC decline and have a probable but less certain effect on mortality. ISHLT guidance favors early referral at diagnosis of a UIP pattern rather than waiting for end-stage disease.
• Whole-lung lavage for autoimmune pulmonary alveolar proteinosis.

Contraindicated / harmful

• Prednisone + azathioprine + N-acetylcysteine in IPF: increased death and hospitalization (PANTHER-IPF) — do not treat IPF with immunosuppression.
• Nintedanib in pregnancy (teratogenic) and caution with anticoagulants (VEGF-mediated bleeding risk).

Disease-related

• Acute exacerbation of IPF (emergency): acute worsening of dyspnea over <1 month with new bilateral ground-glass opacities superimposed on a UIP pattern and no identified cardiac or infectious cause; histology shows diffuse alveolar damage layered on fibrosis. Carries very high inpatient mortality and often precipitates transplant listing.
• Group 3 pulmonary hypertension and cor pulmonale: capillary bed destruction plus chronic hypoxic vasoconstriction raises pulmonary vascular resistance; signals are a loud P₂, RV heave, JVD, edema, and a DLCO that falls out of proportion to FVC. An exception to the general rule against vasodilators is inhaled treprostinil, which is approved for PH-ILD (INCREASE trial); systemic vasodilators (PDE5 inhibitors, endothelin receptor antagonists) remain discouraged because they blunt hypoxic vasoconstriction and worsen shunt.
• Chronic hypoxemic then hypercapnic respiratory failure: late respiratory-muscle fatigue converts early respiratory alkalosis into acidosis.
• Lung cancer: fibrosis is a field of chronic epithelial injury; IPF markedly increases bronchogenic carcinoma risk, and asbestos exposure raises risk of both bronchogenic carcinoma (more common; risk is multiplicative with cigarette smoking) and mesothelioma (more specific for asbestos; risk is NOT increased by smoking).
• Infection: silicosis impairs alveolar macrophage function and predisposes to tuberculosis (silicotuberculosis) — screen with IGRA/TST.
• Pneumothorax (emergency): rupture of subpleural cysts in Langerhans cell histiocytosis, lymphangioleiomyomatosis, or honeycomb lung; sudden pleuritic pain with unilateral absent breath sounds.

Treatment-related

• Nintedanib: diarrhea (most common), transaminase elevation, and bleeding/impaired wound healing from VEGFR blockade — monitor LFTs.
• Pirfenidone: nausea, anorexia, photosensitivity rash (counsel on sun protection), hepatotoxicity.
• Glucocorticoids/immunosuppressants: hyperglycemia, osteoporosis, adrenal suppression, and opportunistic infection (Pneumocystis jirovecii prophylaxis with TMP-SMX at sustained high-dose steroid or combination immunosuppression).
• Cyclophosphamide: hemorrhagic cystitis and bladder cancer (mesna prophylaxis); marrow suppression.
• Oxygen therapy: fire risk, nasal mucosal drying; in advanced disease, CO₂ retention with excessive FiO₂.

• The PFT signature: FVC and TLC both low, but FEV₁/FVC normal or increased — the ratio is the discriminator from obstruction. Low DLCO points to parenchymal (intrinsic) disease; normal or high DLCO with low TLC points to extrapulmonary restriction (kyphoscoliosis, obesity, neuromuscular disease with reduced maximal inspiratory pressure).
• Single best next step for a patient with Velcro crackles, clubbing, and restrictive PFTs: HRCT of the chest, not lung biopsy. A definite UIP pattern (subpleural, basal, reticulation, traction bronchiectasis, honeycombing) in the right clinical context makes IPF a clinical diagnosis without biopsy.
• Histologic buzzwords for UIP: temporal and spatial heterogeneity, fibroblastic foci, honeycomb lung. NSIP is the opposite — temporally uniform and ground-glass predominant, and it is the pattern most associated with systemic sclerosis.
• The association examiners love: upper-lobe versus lower-lobe distribution. Silicosis, coal worker's pneumoconiosis, sarcoidosis, ankylosing spondylitis, and berylliosis are upper-lobe; asbestosis, IPF, and CTD-ILD are lower-lobe/subpleural.
• Asbestos pearls: ferruginous bodies (golden-brown, beaded, iron-coated fibers) and pleural plaques (calcified, diaphragm/parietal pleura, benign markers of exposure). The commonest asbestos-associated malignancy is bronchogenic carcinoma, not mesothelioma — that is the classic distractor.
• Do not give steroids for IPF. Immunosuppression increased mortality in PANTHER-IPF; the answer is an antifibrotic (pirfenidone or nintedanib) plus transplant referral.
• Sarcoidosis: non-caseating granulomas, bilateral hilar lymphadenopathy, hypercalcemia from granuloma 1α-hydroxylase, Schaumann and asteroid bodies. Löfgren syndrome (erythema nodosum, hilar adenopathy, arthritis) often resolves spontaneously.
• Named syndromes: Caplan syndrome = pneumoconiosis plus rheumatoid nodules; eggshell calcification = silicosis; Birbeck granules/CD1a = Langerhans cell histiocytosis.